GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » EBITDA Margin %

Progyny (Progyny) EBITDA Margin % : 6.92% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Progyny EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Progyny's EBITDA for the three months ended in Mar. 2024 was $19 Mil. Progyny's Revenue for the three months ended in Mar. 2024 was $278 Mil. Therefore, Progyny's EBITDA margin for the quarter that ended in Mar. 2024 was 6.92%.


Progyny EBITDA Margin % Historical Data

The historical data trend for Progyny's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny EBITDA Margin % Chart

Progyny Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial 5.14 2.97 6.72 3.17 5.92

Progyny Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.02 5.62 6.68 5.35 6.92

Competitive Comparison of Progyny's EBITDA Margin %

For the Health Information Services subindustry, Progyny's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progyny's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Progyny's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Progyny's EBITDA Margin % falls into.



Progyny EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Progyny's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=64.465/1088.598
=5.92 %

Progyny's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=19.239/278.078
=6.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progyny  (NAS:PGNY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Progyny EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Progyny's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Progyny (Progyny) Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Executives
David J Schlanger director, officer: Executive Chairman C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer officer: President 48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston officer: Chief Financial Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski officer: Chief Executive Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz officer: EVP, GC C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean director 185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero officer: EVP, GC and Secretary C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg director
Jennifer Bealer officer: EVP, General Counsel C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton director 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730